Company intelligence / Profile preview

KuDOS Pharmaceuticals

Cambridge, Cambridgeshire, United Kingdom

Ownership: Private
Development stage: Other

Overview

KuDOS Pharmaceuticals developed small molecule modulators of DNA damage response. Lead programs included ATM, MGMT, PRKDC, and PARP pathway inhibitors for oncology indications, with most programs reaching preclinical or discontinued status. Notable collaborations included AstraZeneca. The company was acquired by AstraZeneca, and key clinical activities and IP integrated there.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

AstraZeneca

Beyond the preview

Go deeper on KuDOS Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KuDOS Pharmaceuticals.

Explore the full profile